Protocol Ledger

NCT06740526 · Phase II · ACTIVE NOT RECRUITING

Phase 2b Open-Label Repeat Kidney Biopsy Study

Interventional Phase II clinical trial protocol NCT06740526 sponsored by Otsuka Pharmaceutical Development & Commercialization in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-05 Enrollment: 56 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06740526
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)56 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06740526
Protocol FieldVerified Registry Value
NCT IdentifierNCT06740526
Consolidated Lead SponsorOtsuka Pharmaceutical Development & Commercialization
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment56 participants (ACTUAL)
Registered Start Date2024-12-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI